← Back to all trials
Completed
NCT06759077
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Conditions: Kidney Diseases
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 126
Sponsor: Al-Azhar University
Location: faculty of pharmacy (girls )ALAzhar university Cairo
Summary
If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life
Eligibility Criteria
Inclusion Criteria:
* Patients with CKD stage5 (i.e., eGFR \< 15 mL/min/1.73m2) (Inker et al., 2021)
Exclusion Criteria:
* patients who refuse to sign consent
* Patients with acute heart failure , will exclude patients with known prior ischemic heart diseases or ischemic cardiomyopathy
* Autosomal dominant polycystic kidney disease (ADPKD).
* Type 1 diabetes mellitus
* History of ketoacidosis in the last year.
* Known hypersensitivity to SGLT2 inhibitors.
* Known severe hepatic impairment (Child-Pugh class C)
* Pregnant or breastfeeding females
Source: ClinicalTrials.gov (NCT06759077). StuddyBuddy aggregates publicly available trial information.
